CEL-SCI Corporation Shares Near 52-Week Low - Market Mover
The shares closed 1.0% above its 52-week low of $6.10, with trading volume lower than its 30 day average
Jan 13, 2022 by Kwhen Finance Editors
CEL-SCI Corporation (CVM) shares closed today at 1.0% above its 52 week low of $6.10, giving the company a market cap of $279M. The stock is currently down 8.9% year-to-date, down 51.4% over the past 12 months, and up 72.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%.
Trading Activity
- Trading volume this week was 68.9% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.1.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Fundamentals & Catalysts
- Over the past 12 months the company generated $-30,477,448 in earnings before interest and taxes from $224,432 in revenue. It currently holds $17 million in cash and $5 million in debt.
- Its forward price-to-earnings (P/E) ratio of 0 is higher than its current P/E ratio of -8.21, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 0.00. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.65 which means it currently has $1.65 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 30.00. This means that the stock is trading at a premium of 30 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 3920.57.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 3895.94.
P/E
-8.21
EBITDA
$-30,477,448
P/Book
30.00
Mkt Cap
$279M
P/Sales
3920.57
Revenue
$224,432
EPS (TTM)
-0.86
PEG Ratio
0.00
EV/Revenue
3895.94
Total Cash
$17M
Debt/Equity
1.65
Forward P/E
0.00
Current Debt
$5M
Gross Profit
$224,432
Dividend Date
-
Earnings Date
2022-02-11
Profit Margin
-156.37
Revenue/Share
0.01
Total Revenue
$224,432
Enterprise Val
$874M
Put/Call Ratio
1.12
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| CEL-SCI Corporation | -4.8 | -8.9 | -51.4 | -83.9 | 7.9 |
| Dow Jones Industrial Average | 0.1 | -0.2 | 18.9 | -1.6 | 23.8 |
| S&P 500 Index | 0.3 | -1.1 | 25.7 | -1.7 | 29.8 |
| Health Care | -0.3 | -3.5 | 14.4 | -4.5 | 22.6 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by -387.6%
- The company's stock price performance over the past 12 months lags the peer average by 205.7%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| CEL-SCI Corporation | CVM | -8.2 | -8.9 | -51.4 | -83.9 | 7.9 |
| Peer Avg | N/A | -48.7 | 3.1 | -16.8 | -39.0 | 28.8 |
| Johnson & Johnson | JNJ | 25.2 | 0.1 | 10.2 | -4.6 | 14.1 |
| AMGEN Inc. | AMGN | 23.3 | 3.3 | 0.8 | -13.4 | 17.0 |
| Teva- Pharmaceutical Industries Ltd. - ADR | TEVA | 13.8 | 13.4 | -20.2 | -31.2 | 18.4 |
| Biocryst Pharmaceuticals Inc. | BCRX | -13.0 | 18.6 | 118.8 | -9.7 | 111.3 |
| Emergent Biosolutions Inc | EBS | 12.1 | 17.1 | -48.5 | -60.5 | 68.3 |
| Xencor Inc | XNCR | -535.7 | -5.9 | -22.8 | -34.8 | 26.3 |
| Curis Inc | CRIS | -8.7 | -21.2 | -64.2 | -78.4 | 18.2 |
| CASI Pharmaceuticals Inc | CASI | -2.4 | -1.3 | -73.5 | -79.7 | 7.5 |
| Titan Pharmaceuticals, Inc. (de) | TTNP | -1.2 | 6.9 | -68.7 | -77.2 | 7.1 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: